China Heparin Quality Under Pressure Again, Congress Warns FDA
Executive Summary
US House committee requests FDA commissioner to provide a contingency response plan should pressures on China's heparin supply chain trigger more of the economically motivated adulteration that killed scores of US patients in 2008.
You may also be interested in...
Is Another Heparin Crisis Looming? Congress Raises Alarm, Demands US FDA Briefing
The FDA must explain how it will prevent heparin adulteration as a virus kills pigs in China again.
Heparin Adulteration Triggered Pharmaceutical Identity Crisis
Pharmaceutical identity crisis arises after ingredients are mimicked by cheap, deadly substitutes. Chemical sleuths tell how they found the melamine cyanurate, oversulfated chondroitin sulfate and diethylene glycol that were hidden in pet food, heparin and cold remedies. Efforts to better identify drug ingredients takes on new urgency with melamine spreading to infant formula and rumors of possible attempts to devise a new heparin adulterant. As instrumental compendial tests are added to monographs, industry, legislators, regulators and compendial organizations grapple with broader implications of this new type of adulteration. U.S. Pharmacopeia leadership talks about establishing a massive standardized spectral library that could be accessed using remote analyzers to instantly identify ingredients, impurities and adulterants.
The Quality Lowdown: No Longer Stoppered By Pandemic, US FDA Finds Serious Problems
Some filling lines and API plants fared poorly in post-pandemic inspections, with shortfalls identified in sterility assurance and impurity control. Zhejiang Tianyu and System Kosmetik got warning letters. Alvotech, Cipla and Aurobindo got Form 483 reports posted on the FDA website.